TARG on NASDAQ
Targanta Therapeutics Corporation
Targanta Therapeutics Corporation was a biopharmaceutical company headquartered in Cambridge, Massachusetts. The company also had operations in Indianapolis, Montreal and Toronto. Targanta completed its initial public offering on October 9, 2007 and traded on the Nasdaq market under the symbol: TARG.3 It was founded in 1997.1 Wikipedia text CC BY-SA 4.0
Price unavailable
Last updated Oct 21, 2026.
Overview
- TickerTARG on NASDAQ1
- Industrybiotechnology1
- HeadquartersCambridge1
- Websitewww.themedicinescompany.com
- Incorporated inDE4
- Business address222 Third Avenue, Suite 2300, Cambridge, Ma 021424
See how the biggest companies compare on our leaderboards
Targanta Therapeutics Corporation was a biopharmaceutical company headquartered in Cambridge, Massachusetts. The company also had operations in Indianapolis, Montreal and Toronto. Targanta completed its initial public offering on October 9, 2007 and traded on the Nasdaq market under the symbol: TARG. Targanta was acquired by The Medicines Company in 2009.3
Corporate structure
Targanta Therapeutics Corporation is part of a group headed by CorMedix Inc.. 7 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
- CorMedix Inc. Berkeley Heights, New Jersey, United States
- Targanta Therapeutics Corporation Cambridge
- CEM-102 Pharmaceuticals, Inc. Subsidiary · Delaware, United States
- Cempra Pharmaceuticals, Inc. Subsidiary · Delaware, United States
- Melinta Subsidiary Corp. Subsidiary · Delaware, United States
- Melinta Therapeutics, LLC Subsidiary · Delaware, United States
- Rempex Pharmaceuticals, Inc. Subsidiary · Delaware, United States
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC. Each entity in the chart links to its source.
Leadership
Who has led Targanta Therapeutics Corporation, and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
- Chief executive officerMark Leuchtenberger Oct 10, 2007 to Feb 8, 20085
- PresidentMark Leuchtenberger Oct 10, 2007 to Feb 8, 20085
- Chief financial officerGeorge A. Eldridge Oct 10, 2007 to Feb 8, 20086
Board members and other officers (13)
- Chief Commercial OfficerMona Haynes Mar 4, 2008 to Mar 4, 20087
- Chief Development OfficerPierre E. Etienne Oct 10, 2007 to Feb 8, 20088
- Chief Scientific OfficerThomas R. Parr Jr. Oct 10, 2007 to Feb 8, 20089
- Board memberRosemary A. Crane Aug 26, 2008 to Aug 26, 200810
- Board memberStéphane Bancel Aug 26, 2008 to Aug 26, 200811
- Board memberDilip J. Mehta Md. Phd. Oct 10, 2007 to Feb 27, 200912
- Board memberEric M. Gordon Oct 10, 2007 to Feb 27, 200913
- Board memberGaren G. Bohlin Oct 10, 2007 to Jun 3, 200814
- Board memberJay Venkatesan Oct 10, 2007 to Jun 3, 200815
- Board memberJeffrey Courtney Oct 10, 2007 to Feb 27, 200916
- Board memberMark Leuchtenberger Oct 10, 2007 to Feb 8, 20085
- Board memberRobin Joan Steele Oct 10, 2007 to Oct 10, 200717
- Board memberWilliam W. Crouse Oct 10, 2007 to Feb 27, 200918
Timeline
SEC filer profile
How Targanta Therapeutics Corporation is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARTarganta Therapeutics Corp.2
- CIK0001398161
- Employer ID (EIN)20-39710772
- Incorporated inDelaware2
- Fiscal year endsDecember 312
- Industry code (SIC)2834 Pharmaceutical Preparations2
- Business address222 Third Avenue, Suite 2300, Cambridge, MA 021422
- Phone(617) 557-90202
- On EDGAR sinceMay 11, 20072
- Filings138 in all: 4 (24), 3 (19), 8-K (18), SC 13G (9), SC 13G/A (9), S-1/A (5), SC 14D9/A (5), 10-Q (4)2
All 36 form types
SC TO-C (4), SC TO-T/A (4), CORRESP (3), EFFECT (3), SC14D9C (3), CT ORDER (2), FWP (2), SC 13D (2), SC 13D/A (2), UPLOAD (2), 10-K (1), 15-12B (1), 25-NSE (1), 4/A (1), 424B4 (1), 8-A12B (1), 8-K/A (1), ARS (1), CERTNAS (1), DEF 14A (1), POS AM (1), REGDEX (1), S-1 (1), S-3 (1), S-8 (1), S-8 POS (1), SC 14D9 (1), SC TO-T (1)
- Latest filingsAnnual report (10-K) Mar 27, 2008
Quarterly report (10-Q) Nov 12, 2008
Proxy statement (DEF 14A) Apr 28, 2008
Latest 8-K (8-K) Mar 2, 2009
Links
- Websitewww.themedicinescompany.com1
- WikipediaTarganta Therapeutics Corporation
- WikidataQ7685835
- SEC EDGARCIK 1398161
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10SEC EDGARRosemary A. Crane, Board member
- 11SEC EDGARStéphane Bancel, Board member
- 12
- 13SEC EDGAREric M. Gordon, Board member
- 14SEC EDGARGaren G. Bohlin, Board member
- 15SEC EDGARJay Venkatesan, Board member
- 16SEC EDGARJeffrey Courtney, Board member
- 17SEC EDGARRobin Joan Steele, Board member
- 18SEC EDGARWilliam W. Crouse, Board member